{
 "query": "evolocumab",
 "ingredient": "evolocumab",
 "slug": "evolocumab",
 "rxcui": "1665684",
 "brands": [
  "Repatha"
 ],
 "names": [
  "evolocumab"
 ],
 "classes": [],
 "alternatives": [],
 "label": {},
 "faers": {
  "total": 161420,
  "serious": 26961,
  "death": 2043,
  "hospitalization": 8660,
  "primary_suspect": 161404,
  "top_reactions": [
   [
    "Device Difficult To Use",
    32925
   ],
   [
    "Drug Dose Omission By Device",
    24638
   ],
   [
    "Wrong Technique In Product Usage Process",
    22365
   ],
   [
    "Accidental Exposure To Product",
    16804
   ],
   [
    "Injection Site Pain",
    10927
   ],
   [
    "Product Storage Error",
    6676
   ],
   [
    "Back Pain",
    5587
   ],
   [
    "Myalgia",
    5422
   ],
   [
    "Drug Dose Omission",
    4929
   ],
   [
    "Injection Site Bruising",
    4800
   ],
   [
    "Device Use Error",
    4250
   ],
   [
    "Arthralgia",
    4061
   ],
   [
    "Fatigue",
    4061
   ],
   [
    "Injection Site Haemorrhage",
    4029
   ],
   [
    "Off Label Use",
    3936
   ]
  ],
  "by_year": {
   "2019": 9722,
   "2020": 8998,
   "2021": 10476,
   "2022": 12349,
   "2023": 24557,
   "2024": 25528,
   "2025": 7905,
   "2026": 6033
  },
  "by_year_primary": {
   "2019": 9722,
   "2020": 8998,
   "2021": 10476,
   "2022": 12347,
   "2023": 24555,
   "2024": 25528,
   "2025": 7899,
   "2026": 6027
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 1,
  "nda": 0,
  "anda": 0,
  "first_approval": "20150827",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [
   "AMGEN INC"
  ],
  "unapproved": false,
  "first_approval_fmt": "08/27/2015"
 },
 "trials": {
  "total": 165,
  "completed": 82,
  "terminated": 19,
  "with_results": 61,
  "industry": 85,
  "phase3": 43,
  "results_share": 0.7439024390243902,
  "terminated_share": 0.11515151515151516
 },
 "pubmed": {
  "rct": 102,
  "meta": 28,
  "recent_rct": 44,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 5741285.3,
  "records": 77193,
  "by_name": [
   [
    "Repatha",
    5741285.3
   ]
  ],
  "names_checked": [
   "evolocumab",
   "Repatha"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 2245760,
  "beneficiaries": 459932,
  "spend": 1962120377.2399998,
  "by_brand": [
   {
    "brand": "Repatha Sureclick",
    "claims": 1943941,
    "per_claim": 879.44526509,
    "is_generic": false
   },
   {
    "brand": "Repatha Syringe",
    "claims": 233776,
    "per_claim": 838.34150144,
    "is_generic": false
   },
   {
    "brand": "Repatha Pushtronex",
    "claims": 68043,
    "per_claim": 831.04134591,
    "is_generic": false
   }
  ],
  "per_claim": 873.6999399935878
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": {
  "years": [
   "2024",
   "2025",
   "2026"
  ],
  "reports_recent": 39454,
  "fills": 2245760,
  "per_million": 17568.217440866345,
  "ratio": 6.344722368767093,
  "median": 2768.949753790441
 },
 "scores": {
  "safety": {
   "score": 85,
   "letter": "B",
   "why": [
    "17,568 FDA reports naming it as the suspect drug per million Medicare fills, 6.3x the median drug on this site (-15)",
    "Death share in reports is near or below the FAERS average (0.1x)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 62,
   "letter": "D",
   "why": [
    "102 randomized trials and 28 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 100,
   "letter": "A",
   "why": [
    "No recalls on record since 2016"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 70,
   "letter": "C",
   "why": [
    "Pharma paid doctors $5,741,285 tied to this drug last year (-30)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 40,
   "letter": "F",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "No same-class alternatives found: little leverage to switch (-30)"
   ],
   "weight": 0.1
  }
 },
 "total": 75,
 "grade": "C",
 "questions": [
  "The most-reported problems in FDA's adverse event data are device difficult to use, drug dose omission by device, wrong technique in product usage process, accidental exposure to product. How would we recognize and handle those?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}